Steven Gutman

2.0k total citations
42 papers, 1.3k citations indexed

About

Steven Gutman is a scholar working on Physiology, Molecular Biology and Pharmacology. According to data from OpenAlex, Steven Gutman has authored 42 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Physiology, 9 papers in Molecular Biology and 8 papers in Pharmacology. Recurrent topics in Steven Gutman's work include Biomedical Ethics and Regulation (8 papers), Statistical Methods in Clinical Trials (7 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Steven Gutman is often cited by papers focused on Biomedical Ethics and Regulation (8 papers), Statistical Methods in Clinical Trials (7 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Steven Gutman collaborates with scholars based in United States, Thailand and Australia. Steven Gutman's co-authors include Larry G. Kessler, Joseph Hackett, Sheila E. Taube, John S. Rodman, Caroline C. Sigman, Lisa M. McShane, Janet Woodcock, Konstantin Chumakov, Lawrence J. Lesko and Raj K. Puri and has published in prestigious journals such as JAMA, Nature Genetics and Nature reviews. Cancer.

In The Last Decade

Steven Gutman

41 papers receiving 1.2k citations

Peers

Steven Gutman

ONCOL

PRM

Zhu Feng China

Daniel S. Zaharko United States

Annamaria Catino Italy

Weifeng Zhu China

Xuzhen Qin China

Hui Qin China

Guodong Zhu China

Walter Jeske United States

Frédéric Pinguet France

Dominique Trudel Canada

Zhu Feng China

Steven Gutman

518 ×0.9

76 ×0.3

261 ×1.3

212 ×1.2

ONCOL

222 ×1.5

PRM

Citations per year, relative to Steven Gutman Steven Gutman (= 1×) peers Zhu Feng

Countries citing papers authored by Steven Gutman

Since Specialization

Citations

This map shows the geographic impact of Steven Gutman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Gutman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Gutman more than expected).

Fields of papers citing papers by Steven Gutman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Gutman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Gutman. The network helps show where Steven Gutman may publish in the future.

Co-authorship network of co-authors of Steven Gutman

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Gutman. A scholar is included among the top collaborators of Steven Gutman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Gutman. Steven Gutman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Taube, Sheila E., Gary M. Clark, Janet Dancey, et al.. (2009). A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment. JNCI Journal of the National Cancer Institute. 101(21). 1453–1463. 83 indexed citations

Mansfield, Elizabeth, et al.. (2007). Biomarkers for pharmacogenetic and pharmacogenomic studies: Locking down analytical performance. Drug Discovery Today Technologies. 4(1). 17–20. 2 indexed citations

Mansfield, Elizabeth, et al.. (2007). Biomarkers for pharmacogenetic and pharmacogenomic studies: special issues in analytical performance. Drug Discovery Today Technologies. 4(1). 21–24. 1 indexed citations

Težak, Živana, et al.. (2006). FDA perspectives on potential microarray-based clinical diagnostics. Human Genomics. 2(4). 236–236. 13 indexed citations

Frueh, Felix W., et al.. (2006). Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. The Pharmacogenomics Journal. 6(5). 296–300. 10 indexed citations

Gutman, Steven & Larry G. Kessler. (2006). The US Food and Drug Administration perspective on cancer biomarker development. Nature reviews. Cancer. 6(7). 565–571. 129 indexed citations

Mansfield, Elizabeth, Timothy J. O’Leary, & Steven Gutman. (2005). Food and Drug Administration Regulation of in Vitro Diagnostic Devices. Journal of Molecular Diagnostics. 7(1). 2–7. 33 indexed citations

Bast, Robert C., Hans Lilja, Nicole Urban, et al.. (2005). Translational Crossroads for Biomarkers. Clinical Cancer Research. 11(17). 6103–6108. 63 indexed citations

Hammond, M. Elizabeth, Peter E. Barker, Sheila E. Taube, & Steven Gutman. (2003). Standard reference material for Her2 testing: report of a National Institute of Standards and Technology-sponsored Consensus Workshop.. PubMed. 11(2). 103–6. 27 indexed citations

10.

Petricoin, Emanuel F., Joseph Hackett, Lawrence J. Lesko, et al.. (2002). Medical applications of microarray technologies: a regulatory science perspective. Nature Genetics. 32(S4). 474–479. 166 indexed citations

11.

Gutman, Steven. (2002). Regulatory issues in tumor marker development. Seminars in Oncology. 29(3). 294–300. 8 indexed citations

12.

Robinowitz, Max & Steven Gutman. (1999). FDA's new regulatory paradigms for in vitro diagnostic devices. Cytotherapy. 1(4). 353–357. 2 indexed citations

13.

Gutman, Steven. (1999). The Role of Food and Drug Administration Regulation of In Vitro Diagnostic Devices—Applications to Genetics Testing. Clinical Chemistry. 45(5). 746–749. 17 indexed citations

14.

Gutman, Steven. (1998). Update on FDA Regulation of In Vitro Diagnostic Devices. JAMA. 280(2). 190–190. 4 indexed citations

15.

Gutman, Steven & Carolyn A. Tylenda. (1997). Regulatory Issues Unique to Clinical Trials on Periodontal Diagnostic Methods and Devices. Annals of Periodontology. 2(1). 108–112. 1 indexed citations

16.

Gutman, Steven. (1996). Food and Drug Administration (FDA)'s impact on laboratory performance: FDA's perspective. Clinical Chemistry. 42(5). 786–789. 1 indexed citations

17.

Shen, Emily S., Steven Gutman, & James R. Olson. (1991). Comparison of 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin‐mediated hepatotoxicity in C57BL/6J and DBA/2J mice. Journal of Toxicology and Environmental Health. 32(4). 367–381. 20 indexed citations

18.

Lees, Hazel A., et al.. (1988). Effect of nitroblue tetrazolium concentration on the fructosamine assay for quantifying glycated protein.. Clinical Chemistry. 34(10). 2106–2111. 19 indexed citations

19.

Heller, Knut J., et al.. (1987). Clinical significance of dipstick-negative, sediment-positive urines: two reagent dipsticks compared.. PubMed. 33(3). 418–418. 2 indexed citations

20.

Nieman, Lynnette K., et al.. (1983). Effect of end-stage renal disease on responsiveness to calmodulin and thyroid hormone of calcium-ATPase in human red blood cells.. PubMed. 16. S167–70. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact